相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry
Roger M. Lyons et al.
LEUKEMIA RESEARCH (2014)
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
Michel Delforge et al.
LEUKEMIA RESEARCH (2014)
Validation of Disability Status, a Claims-based Measure of Functional Status for Cancer Treatment and Outcomes Studies
Amy J. Davidoff et al.
MEDICAL CARE (2014)
Current therapy of myelodysplastic syndromes
Amer M. Zeidan et al.
BLOOD REVIEWS (2013)
Lenalidomide Performance in the Real World Patterns of Use and Effectiveness in a Medicare Population With Myelodysplastic Syndromes
Amer M. Zeidan et al.
CANCER (2013)
A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes
Amy J. Davidoff et al.
JOURNAL OF GERIATRIC ONCOLOGY (2013)
Iron chelation therapy in myelodysplastic syndromes: where do we stand?
Mhairi Mitchell et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy
Tobias Gerhard et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Deferasirox treatment of iron-overloaded chelation-naive and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange
Norbert Gattermann et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes
Amy J. Davidoff et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes
Norbert Gattermann et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients With Myelodysplastic Syndrome
Alan F. List et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Improved survival in MDS patients receiving iron chelation therapy - A matched pair analysis of 188 patients from the Dusseldorf MDS registry
Judith Neukirchen et al.
LEUKEMIA RESEARCH (2012)
Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis
Heather A. Leitch et al.
LEUKEMIA RESEARCH (2012)
Dynamic marginal structural modeling to evaluate the comparative effectiveness of more or less aggressive treatment intensification strategies in adults with type 2 diabetes
Romain Neugebauer et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
Controversies surrounding iron chelation therapy for MDS
Heather A. Leitch
BLOOD REVIEWS (2011)
Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
Angel F. Remacha et al.
ANNALS OF HEMATOLOGY (2010)
Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes
Hussam Ghoti et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries
Stuart L. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
Christian Rose et al.
LEUKEMIA RESEARCH (2010)
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes
Peter L. Greenberg et al.
LEUKEMIA RESEARCH (2010)
Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices
Anastasios Raptis et al.
TRANSFUSION (2010)
Deferasirox in MDS patients with transfusion-caused iron overload-a phase-II study
Georgia Metzgeroth et al.
ANNALS OF HEMATOLOGY (2009)
Estimating Antihypertensive Effects of Combination Therapy in an Observational Study Using Marginal Structural Models
Masahiro Sugihara et al.
BIOMETRICAL JOURNAL (2009)
Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?
Vinod Pullarkat
BLOOD (2009)
The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study
Francesca Tentori et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Traditional versus marginal structural models to estimate the effectiveness of beta-blocker use on mortality after myocardial infarction
Joseph A. C. Delaney et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Consensus statement on iron overload in myelodysplastic syndromes
John M. Bennett
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy:: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
Miguel A. Sanz et al.
BLOOD (2008)
Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes
Luca Malcovati
LEUKEMIA RESEARCH (2007)
No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2*technique
Eli Konen et al.
AMERICAN JOURNAL OF HEMATOLOGY (2007)
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making
L Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Labile plasma iron in iron overload: redox activity and susceptibility to chelation
BP Esposito et al.
BLOOD (2003)
Oxidative stress and the myelodysplastic syndromes
MJ Farquhar et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2003)
Iron toxicity and chelation therapy
RS Britton et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2002)
Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures
MA Hernán et al.
STATISTICS IN MEDICINE (2002)
Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the physicians' health study
NR Cook et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2002)
Marginal structural models and causal inference in epidemiology
JM Robins et al.
EPIDEMIOLOGY (2000)
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men
MA Hernan et al.
EPIDEMIOLOGY (2000)
分享论文
